In HCT-116 colorectal cancer cells with wild-type TP53 expression, AGK2 treatment decreased the effects of several chemotherapeutic drugs, including cisplatin, 5-fluorouracil, oxaliplatin, gefitinib, LY294002, and metformin. Here, TP53 is linked to colorectal cancer.